New stock news | Canwin technology once again submitted a listing application to the Hong Kong Stock Exchange

06:16 25/03/2026

According to the prospectus, Kesheng Technology is one of the providers of tower-type solar thermal power generation and molten salt storage energy solutions.

According to the disclosure by the Hong Kong Stock Exchange on March 24, Zhejiang Kesheng Technology Co., Ltd. (referred to as Kesheng Technology) has submitted an application for listing on the main board of the Hong Kong Stock Exchange with China Securities Co., Ltd. International as its exclusive sponsor. The company had previously submitted an application for listing to the Hong Kong Stock Exchange on September 24, 2025. According to the prospectus, Kesheng Technology is one of the providers of tower CSP solar power generation and molten salt energy storage solutions. The company focuses on related technical research, equipment sales, and engineering applications, and has the service capabilities from project development, construction consulting to later operation support. From 2021 to 2024, Kesheng Technology provided concentrator systems for 11 solar thermal power plants in China, these systems are the most critical subsystems for molten salt tower CSP power plants, with a total designed installed capacity of 1,250MW.

LEOCH INT'L (00842) issues profit warning, expecting a yearly shareholder loss of no more than approximately 300 million yuan, turning from profit to loss year-on-year.

CHINAHONGQIAO (01378) spent 105 million Hong Kong dollars to repurchase 3.187 million shares on March 24th.

CLOVER BIO-B(02197) announced that the Phase I clinical trial in the United States for repeated administration of RSV vaccine in elderly population has obtained more positive data.

LEOCH INT'L (00842) issues profit warning, expecting a yearly shareholder loss of no more than approximately 300 million yuan, turning from profit to loss year-on-year.

CHINAHONGQIAO (01378) spent 105 million Hong Kong dollars to repurchase 3.187 million shares on March 24th.

CLOVER BIO-B(02197) announced that the Phase I clinical trial in the United States for repeated administration of RSV vaccine in elderly population has obtained more positive data.